Ying-Cheng Chiang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6682281/publications.pdf

Version: 2024-02-01

361413 361022 1,326 49 20 35 citations h-index g-index papers 50 50 50 2369 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Leiomyomatosis peritonealis disseminata in laparoscopic port site and abdomino-pelvic cavity: A case report. Radiology Case Reports, 2022, 17, 293-297.	0.6	2
2	Preoperative magnetic resonance imaging predicts clinicopathological parameters and stages of endometrial carcinomas. Cancer Medicine, 2022, 11, 993-1004.	2.8	4
3	Hyaluronan-Loaded Liposomal Dexamethasone–Diclofenac Nanoparticles for Local Osteoarthritis Treatment. International Journal of Molecular Sciences, 2021, 22, 665.	4.1	28
4	Factors Influencing the Discordancy Between Intraoperative Frozen Sections and Final Paraffin Pathologies in Ovarian Tumors. Frontiers in Oncology, 2021, 11, 694441.	2.8	6
5	Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A populationâ€based analysis. Cancer Medicine, 2021, 10, 6845-6854.	2.8	3
6	Ovarian cancer risk score predicts chemo-response and outcome in epithelial ovarian carcinoma patients. Journal of Gynecologic Oncology, 2021, 32, e18.	2.2	7
7	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. Frontiers in Oncology, 2021, 11 , 675972 .	2.8	21
8	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	3.2	4
9	Outcome and Subsequent Pregnancy after Fertility-Sparing Surgery of Early-Stage Cervical Cancers. International Journal of Environmental Research and Public Health, 2020, 17, 7103.	2.6	3
10	CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells. Endocrine-Related Cancer, 2019, 26, 73-88.	3.1	14
11	Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center. International Journal of Environmental Research and Public Health, 2019, 16, 2561.	2.6	9
12	Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies. Frontiers in Pharmacology, 2019, 10, 426.	3.5	21
13	Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. Cancers, 2019, 11, 1400.	3.7	45
14	Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers, 2019, 11, 270.	3.7	19
15	Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Cancer Letters, 2019, 444, 20-34.	7.2	13
16	Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation. Cancer Letters, 2018, 425, 152-163.	7.2	31
17	Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment. Molecular Therapy, 2018, 26, 404-419.	8.2	33
18	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. Epigenomics, 2018, 10, 1397-1413.	2.1	14

#	Article	IF	CITATIONS
19	Factors predicting parametrial invasion in patients with early-stage cervical carcinomas. PLoS ONE, 2018, 13, e0204950.	2.5	12
20	Risk factors associated with failure of treatment for cesarean scar pregnancy. International Journal of Gynecology and Obstetrics, 2017, 138, 28-36.	2.3	9
21	Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 442-448.	1.3	13
22	Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies. Frontiers in Pharmacology, 2017, 8, 800.	3.5	12
23	Malignant transformation of ovarian mature cystic teratoma into squamous cell carcinoma: a Taiwanese Gynecologic Oncology Group (TGOG) study. Journal of Gynecologic Oncology, 2017, 28, e69.	2.2	40
24	Genomewide copy number analysis of MÃ $\frac{1}{4}$ llerian adenosarcoma identified chromosomal instability in the aggressive subgroup. Modern Pathology, 2016, 29, 1070-1082.	5.5	28
25	Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine. American Journal of Cancer Research, 2016, 6, 157-72.	1.4	5
26	Standardized uptake value and apparent diffusion coefficient of endometrial cancer evaluated with integrated wholeâ€body PET/MR: Correlation with pathological prognostic factors. Journal of Magnetic Resonance Imaging, 2015, 42, 1723-1732.	3.4	45
27	Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, <scp>PTEN</scp> expression, and <scp>ARID</scp> 1A expression. Histopathology, 2015, 66, 517-528.	2.9	34
28	Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Modern Pathology, 2015, 28, 303-311.	5.5	31
29	Establishment of a New Ovarian Cancer Cell Line CA5171. Reproductive Sciences, 2015, 22, 725-734.	2.5	5
30	Outcome of patients with recurrent adult-type granulosa cell tumors – A Taiwanese Gynecologic Oncology Group study. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 253-259.	1.3	12
31	Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma. Oncotarget, 2015, 6, 39740-39755.	1.8	33
32	Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. American Journal of Translational Research (discontinued), 2015, 7, 139-52.	0.0	5
33	Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Modern Pathology, 2014, 27, 983-990.	5.5	73
34	Impact of management on the prognosis of pure uterine papillary serous cancer — A Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecologic Oncology, 2014, 133, 221-228.	1.4	30
35	Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Human Pathology, 2014, 45, 2318-2325.	2.0	22
36	Sertoli–Leydig cell tumors of the ovary: A Taiwanese Gynecologic Oncology Group study. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 66-70.	1.3	25

#	Article	IF	CITATIONS
37	High-risk human papillomavirus, other than type $16/18$, in predominantly older Taiwanese women with high-grade cervical preinvasive lesions. Taiwanese Journal of Obstetrics and Gynecology, 2013, 52, 222-226.	1.3	10
38	Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients. Endocrine-Related Cancer, 2013, 20, 213-227.	3.1	19
39	Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. Journal of Gynecologic Oncology, 2013, 24, 342.	2.2	99
40	Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochemical Journal, 2012, 442, 293-302.	3.7	129
41	Cord blood stem-cell-derived dendritic cells generate potent antigen-specific immune responses and anti-tumour effects. Clinical Science, 2012, 123, 347-360.	4.3	12
42	New primers for methylation-specific polymerase chain reaction enhance specificity of detecting STAT1 methylation. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 43-49.	1.3	5
43	Serous ovarian carcinoma patients with high alphaâ€folate receptor had reducing survival and cytotoxic chemoâ€response. Molecular Oncology, 2012, 6, 360-369.	4.6	113
44	A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2012, 124, 244-249.	1.4	96
45	Brain metastases from epithelial ovarian carcinoma: Evaluation of prognosis and managements — A Taiwanese Gynecologic Oncology Group (TGOG) Study. Gynecologic Oncology, 2012, 125, 37-41.	1.4	16
46	Impact of various treatment modalities on the outcome of stage IB1 \hat{a} e"IIA cervical adenocarcinoma. International Journal of Gynecology and Obstetrics, 2011, 112, 135-139.	2.3	8
47	Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis. Molecular Therapy, 2010, 18, 1233-1243.	8.2	85
48	Septic Shock after Conservative Management for Placenta Accreta. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 64-66.	1.3	21
49	Tuberculosis peritonitis. Surgery, 2006, 139, 707-708.	1.9	2